Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Free Cash Flow (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Free Cash Flow for 8 consecutive years, with -$15.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Free Cash Flow fell 3.66% to -$15.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$97.0 million, a 86.65% decrease, with the full-year FY2024 number at -$61.2 million, down 1.61% from a year prior.
  • Free Cash Flow was -$15.4 million for Q3 2025 at Whitehawk Therapeutics, up from -$53.5 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $10.6 million in Q1 2021 to a low of -$53.5 million in Q2 2025.
  • A 5-year average of -$14.5 million and a median of -$14.6 million in 2023 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: skyrocketed 368.11% in 2021, then tumbled 440.66% in 2025.
  • Whitehawk Therapeutics' Free Cash Flow stood at -$12.5 million in 2021, then rose by 6.25% to -$11.7 million in 2022, then surged by 39.64% to -$7.1 million in 2023, then tumbled by 130.61% to -$16.3 million in 2024, then increased by 5.53% to -$15.4 million in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Free Cash Flow are -$15.4 million (Q3 2025), -$53.5 million (Q2 2025), and -$11.9 million (Q1 2025).